About
Activity
-
https://lnkd.in/ggbNPxgu - this is the most in-depth look at Isomorphic Labs to date and really captures the essence of what we have been building…
https://lnkd.in/ggbNPxgu - this is the most in-depth look at Isomorphic Labs to date and really captures the essence of what we have been building…
Liked by David Evans
-
I had an incredible time this week joining John and Demis together with the rest of the AlphaFold 2 team in Stockholm for the Nobel Prize…
I had an incredible time this week joining John and Demis together with the rest of the AlphaFold 2 team in Stockholm for the Nobel Prize…
Liked by David Evans
-
Incredible turnout and energy at our #NeurIPS2024 booth presentation of Isomorphic Labs Thank you all for the great questions and for cheering us on.…
Incredible turnout and energy at our #NeurIPS2024 booth presentation of Isomorphic Labs Thank you all for the great questions and for cheering us on.…
Liked by David Evans
Experience & Education
Licenses & Certifications
Publications
-
Mechanism of action deconvolution of the small-molecule pathological tau aggregation inhibitor Anle138b
Alzheimer’s Research and Therapy
-
Lessons learned in induced fit docking and metadynamics in the Drug Design Data Resource Grand Challenge 2
Journal of Computer Aided Molecular Design
-
Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M1 agonists
Bioorg. Med. Chem. Lett.. 25(19) 4158-63.
-
Discovery of selective RIO2 kinase small molecule ligand
Biochimica et Biophysica Acta
Diphenpyramide, a COX 1, 2 inhibitor, is also a RIO2 kinase small molecule ligand.
Several analogs of diphenpyramide are also RIO2 kinase small molecule ligand.
Diphenpyramide and one of its analogue show good selectivity against other kinases.Other authorsSee publication -
Comparing Global and Local Likelihood Score Thresholds in Multiclass Laplacian-Modified Naive Bayes Protein Target Prediction
Combinatorial Chemistry & High Throughput Screening
-
Connecting gene expression data from connectivity map and in silico target predictions for small molecule mechanism-of-action analysis
Molecular Biosystems
Integrating gene expression profiles with certain proteins can improve our understanding of the fundamental mechanisms in protein–ligand binding. This paper spotlights the integration of gene expression data and target prediction scores, providing insight into mechanism of action (MoA). Compounds are clustered based upon the similarity of their predicted protein targets and each cluster is linked to gene sets using Linear Models for Microarray Data. MLP analysis is used to generate gene sets…
Integrating gene expression profiles with certain proteins can improve our understanding of the fundamental mechanisms in protein–ligand binding. This paper spotlights the integration of gene expression data and target prediction scores, providing insight into mechanism of action (MoA). Compounds are clustered based upon the similarity of their predicted protein targets and each cluster is linked to gene sets using Linear Models for Microarray Data. MLP analysis is used to generate gene sets based upon their biological processes and a qualitative search is performed on the homogeneous target-based compound clusters to identify pathways. Genes and proteins were linked through pathways for 6 of the 8 MCF7 and 6 of the 11 PC3 clusters. Three compound clusters are studied; (i) the target-driven cluster involving HSP90 inhibitors, geldanamycin and tanespimycin induces differential expression for HSP90-related genes and overlap with pathway response to unfolded protein. Gene expression results are in agreement with target prediction and pathway annotations add information to enable understanding of MoA. (ii) The antipsychotic cluster shows differential expression for genes LDLR and INSIG-1 and is predicted to target CYP2D6. Pathway steroid metabolic process links the protein and respective genes, hypothesizing the MoA for antipsychotics. A sub-cluster (verepamil and dexverepamil), although sharing similar protein targets with the antipsychotic drug cluster, has a lower intensity of expression profile on related genes, indicating that this method distinguishes close sub-clusters and suggests differences in their MoA. Lastly, (iii) the thiazolidinediones drug cluster predicted peroxisome proliferator activated receptor (PPAR) PPAR-alpha, PPAR-gamma, acyl CoA desaturase and significant differential expression of genes ANGPTL4, FABP4 and PRKCD [...]
Other authorsSee publication -
Comparative Mode-of-Action Analysis Following Manual and Automated Phenotype Detection in Xenopus laevis
MedChemComm
Given the increasing utilization of phenotypic screens in drug discovery also the subsequent mechanism-of-action analysis gains increased attention. Such analyses are frequently using in silico methods, which have become significantly more popular in recent years. However, identifying phenotype-specific mechanisms of action depends heavily on suitable phenotype identification in the first place, many of which rely on human input and are therefore inconsistent. In this work, we aimed at…
Given the increasing utilization of phenotypic screens in drug discovery also the subsequent mechanism-of-action analysis gains increased attention. Such analyses are frequently using in silico methods, which have become significantly more popular in recent years. However, identifying phenotype-specific mechanisms of action depends heavily on suitable phenotype identification in the first place, many of which rely on human input and are therefore inconsistent. In this work, we aimed at analysing the impact that human phenotype classification has on subsequent in silico mechanism-of-action analysis. To this end, an image analysis application was implemented for the rapid identification of seven high-level phenotypes in Xenopus laevis tadpoles treated with compounds from the National Cancer Institute Diversity Set II. It was found that manual and automated phenotype classification were in agreement with some of the phenotypes (e.g. 73.9% agreement observed for General Morphology abnormality), while this was not the case in others (e.g. Melanophore Migration with 37.6% agreement between both annotations). Based on both annotations, protein targets of active compounds were predicted in silico, and decision trees were generated to understand mechanisms-of-action behind every phenotype. It was found that the automated phenotype categorisation greatly increased accuracy of the results mechanism-of-action model, where it improved the classification accuracy by 9.4%, as well as reducing the tree size by eight nodes and the number of leaves and the depth by three levels. Overall we conclude that consistent phenotype annotations seem to be generally crucial for successful subsequent mechanism-of-action analysis, and this is what we have shown here in the combination of in Xenopus laevis screens in combination with in silico mechanism-of-action analysis.
Other authorsSee publication -
Targeting the DNA minor groove with fused ring dicationic compounds: comparison of in silico screening and a high-resolution crystal structure.
Bioorg. Med. Chem. Lett., 16, 15-19
Other authors -
Folding of the GB1 Hairpin Peptide from Discrete Path Sampling.
J. Chem. Phys., 121, 1080-1090
Other authors -
The Dynamics of Conformational Isomerization in Flexible Biomolecules: Simulating isomerizations in a supersonic free jet with master equation dynamics.
J. Chem. Phys., 120, 148-157
Other authors -
Extending in silico mechanism-of-action analysis by annotating targets with pathways: application to cellular cytotoxicity readouts
Future Medicinal Chemistry
Background: An in silico mechanism-of-action analysis protocol was developed, comprising molecule bioactivity profiling, annotation of predicted targets with pathways and calculation of enrichment factors to highlight targets and pathways more likely to be implicated in the studied phenotype. Results: The method was applied to a cytotoxicity phenotypic endpoint, with enriched targets/pathways found to be statistically significant when compared with 100 random datasets. Application on a smaller…
Background: An in silico mechanism-of-action analysis protocol was developed, comprising molecule bioactivity profiling, annotation of predicted targets with pathways and calculation of enrichment factors to highlight targets and pathways more likely to be implicated in the studied phenotype. Results: The method was applied to a cytotoxicity phenotypic endpoint, with enriched targets/pathways found to be statistically significant when compared with 100 random datasets. Application on a smaller apoptotic set (10 molecules) did not allowed to obtain statistically relevant results, suggesting that the protocol requires modification such as analysis of the most frequently predicted targets/annotated pathways. Conclusion: Pathway annotations improved the mechanism-of-action information gained by target prediction alone, allowing a better interpretation of the predictions and providing better mapping of targets onto pathways.
Other authorsSee publication
Patents
-
Malt-1 modulators
Filed WO2022106857A1
More activity by David
-
I feel incredibly grateful to have been part of this project along with my amazing colleagues Jérémy Besnard, Ross Paveley at Recursion and the GT…
I feel incredibly grateful to have been part of this project along with my amazing colleagues Jérémy Besnard, Ross Paveley at Recursion and the GT…
Liked by David Evans
-
I was interviewed by SVT (national Swedish TV) during the Nobel banquet about my thoughts on how it was to work on AlphaFold and what the prize means…
I was interviewed by SVT (national Swedish TV) during the Nobel banquet about my thoughts on how it was to work on AlphaFold and what the prize means…
Liked by David Evans
-
💡 Pushing Boundaries in Drug Discovery: The Story Behind Our New PDE9A Inhibitor 💡 As the Chief Scientific Officer at Ignota Labs, it’s a…
💡 Pushing Boundaries in Drug Discovery: The Story Behind Our New PDE9A Inhibitor 💡 As the Chief Scientific Officer at Ignota Labs, it’s a…
Liked by David Evans
-
If you’re at #NeurIPS2024 this year, come say hi at our booth 👋 We’re hosting demos of our weather forecasting model GenCast, our AI tools for…
If you’re at #NeurIPS2024 this year, come say hi at our booth 👋 We’re hosting demos of our weather forecasting model GenCast, our AI tools for…
Liked by David Evans
-
Are you curious about the role AI can play in the drug design process? This is your chance to gain insights and get your questions answered by…
Are you curious about the role AI can play in the drug design process? This is your chance to gain insights and get your questions answered by…
Liked by David Evans
-
📣 A huge milestone for Ignota Labs. 🎉 Today, we are announcing the in-licensing of our first fully-owned asset: a proprietary PDE9A inhibitor.…
📣 A huge milestone for Ignota Labs. �� Today, we are announcing the in-licensing of our first fully-owned asset: a proprietary PDE9A inhibitor.…
Liked by David Evans
-
We are looking for stellar ML Engineers! And if you're there, Neurips will be a great time to come speak to us and start the Iso journey
We are looking for stellar ML Engineers! And if you're there, Neurips will be a great time to come speak to us and start the Iso journey
Liked by David Evans
-
We are looking forward to seeing you at NeurIPS 2024 in Vancouver. Come and talk to us about our open ML Research Engineer roles at Isomorphic Labs…
We are looking forward to seeing you at NeurIPS 2024 in Vancouver. Come and talk to us about our open ML Research Engineer roles at Isomorphic Labs…
Liked by David Evans
-
If you are a machine learning engineer passionate about solving drug discovery through ML, come interview with us at NeurIPS 2024. You will be done…
If you are a machine learning engineer passionate about solving drug discovery through ML, come interview with us at NeurIPS 2024. You will be done…
Liked by David Evans
-
Google DeepMind's public policy team have published an article that describes the philosophy and practical experience of the Google DeepMind Science…
Google DeepMind's public policy team have published an article that describes the philosophy and practical experience of the Google DeepMind Science…
Liked by David Evans
-
This should be good. Everything Rebecca Paul touches turns to gold, so maybe she can share how she does it!
This should be good. Everything Rebecca Paul touches turns to gold, so maybe she can share how she does it!
Liked by David Evans
-
I'm honored to be presenting a keynote at the Learning on Graphs Conference (https://logconference.org/) this Friday, November 29th, at 15:00 GMT /…
I'm honored to be presenting a keynote at the Learning on Graphs Conference (https://logconference.org/) this Friday, November 29th, at 15:00 GMT /…
Liked by David Evans
-
After 38 years I'll be leaving Syngenta at the end of November. Many great memories and the opportunity to work with some brilliant people, it will…
After 38 years I'll be leaving Syngenta at the end of November. Many great memories and the opportunity to work with some brilliant people, it will…
Liked by David Evans
Other similar profiles
-
Simon Richards
Connect -
Nanna Ahlsten
Senior computational drug designer at Recusion
Connect -
Catarina Santos
Connect -
Olivier Barbeau
Connect -
Marco Derudas
Senior Drug Designer
Connect -
Martin Saunders
Computational Chemist at GSK (retired)
Connect -
Rob Smith
Associate Director - Cheminformatics
Connect -
Sandeep Pal
Connect -
Jameed Hussain
Principal Scientist & Engineering Manager at Dotmatics
Connect -
Ian Wall
Connect
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named David Evans in United Kingdom
-
David Evans
-
David Evans
-
David Evans
-
David Evans
MD at Anglo
-
David Evans
Leader effectiveness and wellbeing / Organisational cohesion and alignment
2659 others named David Evans in United Kingdom are on LinkedIn
See others named David Evans